Guangzhou Innogen Pharmaceutical Group Co., Ltd. (Stock Code: 2591) disclosed that on 4 February 2026, the Ministry of Agriculture and Rural Affairs of the People’s Republic of China accepted its Investigational New Veterinary Drug application for Efsubaglutide Alfa. This core product targets companion animal diabetes, and Phase I clinical trials are anticipated to begin in the first quarter of 2026.

Management believes that research and development of diabetic medication for companion animals present significant prospects, aligning with the group’s long-term business strategy and offering potential groundwork for future expansion into companion animal drug products. According to pre-clinical trial data, Efsubaglutide Alfa showed positive efficacy and safety results in diabetic management for companion animals, which supports subsequent clinical trials and future registration applications.

A cautionary statement indicates that there is no guarantee of the eventual success of developing or marketing Efsubaglutide Alfa for companion animal diabetes. Shareholders and potential investors are advised to exercise due care when dealing in the company’s shares.